A truncated-dose regimen of daclizumab for prevention of acute rejection in kidney transplant recipients: A single-center experience Academic Article Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Carcinoma, Squamous Cell
  • Carcinoma, Transitional Cell
  • Neoplasms, Multiple Primary
  • Urologic Neoplasms

abstract

  • Daclizumab can decrease the incidence of acute rejection (AR) in renal transplant (RTx) recipients. In this prospective study, 52 RTx patients were divided into two groups according to the dose of daclizumab: 1 mg/kg on day 0 and every 14 days for five doses (group 1, n = 30) or a truncated regimen of 2 mg/kg on day 0 and on the day of discharge (group 2, n = 22). The following variables were recorded: demographics; delayed graft function; AR at 3, 6, and 12 months; time to AR; chronic allograft nephropathy (CAN); and serum creatinine. The overall incidences of AR were 23% and 27% (P = 0.76) in groups 1 and 2, respectively, whereas at 6 months they were 21% and 18% (P = 1.0). Median time to AR was 10 days in group 1 and 94 days in group 2 (P = 0.09). The incidence of CAN was 6.6% in group 1 and 13% in group 2 (P = 0.63). These data suggest that the truncated dose of daclizumab is as effective as the standard regimen for AR prophylaxis.

publication date

  • November 27, 2004

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1097/01.TP.0000140767.67868.F1

PubMed ID

  • 15599323

Additional Document Info

start page

  • 1560

end page

  • 3

volume

  • 78

number

  • 10